Molecular biology-ADMA (asymmetric dimethylarginine) - The inhibitor of nitric oxide (No) synthesis: A new market for vascular pathology

Harefuah

Volumn 144, Issue 9, 2005, Pages 655-659

  Sela, B A ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

ADMA; Atherosclerosis; Endothelial dysfunction; Nitric oxide; Vasodilataion

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ARGININE; BIOLOGICAL MARKER; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ATHEROSCLEROSIS; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; MOLECULAR BIOLOGY; REVIEW; VASODILATATION; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; PATHOLOGY; VASCULAR DISEASE; VASOCONSTRICTION;

ARGININE; BIOLOGICAL MARKERS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASCULAR DISEASES; VASOCONSTRICTION;

EID: 27744532224     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Dayoub H, Achan V, Jacobi J & al, Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation, 2003; 108: 3042-7.
2. Kubes P, Suzuki M & Granger DN, Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci, USA, 1991; 88: 4651-5.
3. Scott-Burden T & Vanhoutte PM, Regulation of smooth muscle cell growth by endothelium-derived factors. Texas Heart Inst J, 1994; 21: 91-7.
4. Valkonen VP, Paiva H, SWalonen JT & al, Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet, 2001; 358: 2127-8.
5. Pereira EC, Bertplami MC, Faludi AA & al, Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic Res, 2003; 37: 529-36.
6. Vallance P, MLeone A, Calver A & al, Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992; 339: 572-5.
7. Achan V, Broadhead M, Malaki M & al, Assymetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Throm Vasc Biol, 2003; 23: 1455-9.
8. Kielstein JT, Böger RH, Bode-Böger SM & al, Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol, 1999; 10: 594-600.
9. Fliser D, Kielstein JT, Bode-Böger SM & al, Asymmetric dimethylarginine (ADMA): a cardiovascular risk factor in patients with renal disease? Kidney Int, 2003; 63 (Suppl 84): S37-S40.
10. Ito A, Tsao PS, Adimoolam S & al, Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation, 1999; 99: 13527-32.
11. Dayoub H, Achan V, Adimoolam S & al, Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation, 2003; 108: 3042-7.
12. Calver A, Collier J, Leone A & al, Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arterial bed of healthy volunteers. J Hum Hyperts, 1993; 7: 193-4.
13. Teerlink T, Nijveldt JR, deJong S & al, Determination of arginine, asymmetric dimethylarginine, and symmetric dimethyl arginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem, 2001; 303: 131-7.
14. Valkonen VP, Päivä H, Salonen JT & al, Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet, 2001; 358: 2127-8.
15. Miyazaki H, Matsuoka H & Cooke JP, Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation, 1999; 99: 1141-6.
16. Yoo JH & Lee SC, Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis, 2001; 158: 425-30.
17. Böger RH, Lenzen H, Hanefeld C & al, Asymmetric dimethylarginine and the risk of coronary heart disease: relationship with traditional risk factors as assessed in the multicenter CARDIAC study. J Am Coll Cardiol, 2004; 43 (Suppl): 515A.
18. Zoccali C, Benedetto FA, Maas R & al, Asymmetric dimehylarginine (ADMA), C-reactive protein and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol, 2002; 13: 490-6.
19. Zoccali C, Bode-Böger SM, Mallamaci F & al, Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet, 2001; 358: 2113-7.
20. Nijveldt RJ, Teerlink T, van der Hoven B & al, Asymmetric dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr, 2003; 22: 23-30.
21. Nieto FJ, Young TB, Lind BK & al, Association of sleep - disordered breathing, sleep apnea and hypertension in a large community based study: Sleep heart health study. JAMA, 2000; 283: 1829-36.
22. Böger RH, Bode-Böger SM, Thiele W & al, Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation, 1997; 95: 2068-74.
23. Boger RH, Bode-Boger SM, Thiele W & al, Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol, 1998; 32: 1336-44.
24. Gokce N, Keaney JF Jr, Hunter LM & al, Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol, 2003; 41: 1769-75.
25. Ohike Y, Kozaki K, Iijima K & al, Amelioration of vascular endothelial dysfunction in Obstructive sleep apnea syndrome by nasal continuous positive airway pressure. Cir J, 2005; 69: 221-6.
26. Ip MS, Lam B, Chan LY & al, Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care, 2000, 162: 2166-71.
27. Hornig B, Arakawa N, Böger RH & al, Plasma levels of ADMAare increased and inversely related to endothelium-mediated vasodilation in patients with chronic heart failure: a new predictor of endothelial dysfunction? Circulation, 1998; 98 (suppl) 1-318 (abs).
28. Azuma H, Sato J, Hamasaki H & al, Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol, 1995; 115: 1001-4.
29. Schwarzacher SP, Lim TT, Wang B & al, Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation, 1997; 95: 1863-9.
30. Asagmi T, Abbasi F, Stuhlinger MC & al, Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism, 2002; 51: 843-6.
31. Stuhlinger MC, Abassi F, Chu JW & al, Relationship between insulin resistence and an endogenous nitric oxide synthase inhibitor. JAMA, 2002; 287: 1420-6.
32. Delles C, Schneider MP, John S & al, Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens, 2002; 15(pt 1): 590-3.
33. Post PM, Verhoeven MO, van der Mooren & al, Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenapausal women. J Clin Endocrinol Metab, 2003; 88: 4221-6.
34. Lu TM, Ding YA, Leu HB & al, Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol, 2004; 15: 157-61.
35. Paiva H, Laakso, Lehtimaki T & al, Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol, 2003; 41: 219-22.
36. Kuhlencordt PJ, Gyurko R, Han F & al, Accelerated atherosclerosis, aortic aneurysm and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation, 2001; 104: 448-54.